<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055962</url>
  </required_header>
  <id_info>
    <org_study_id>E2609-J081-014</org_study_id>
    <nct_id>NCT03055962</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study E2609-J081-014 is a single-center, randomized, double-blind, placebo-controlled study
      conducted to evaluate the safety and tolerability of multiple oral doses of E2609 50
      milligrams (mg), administered once daily for 14 days, in healthy Japanese participants aged
      50 to 85 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and number of participants with any non-serious adverse event</measure>
    <time_frame>up to Day 35 (Termination/Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant laboratory test value</measure>
    <time_frame>Screening; Baseline; Days 4, 8, 11, 14, 20 (Out-Patient Follow-up), and 35 (Termination/Visit 5); up to Day 62 (unscheduled Follow-up visits)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant vital sign value</measure>
    <time_frame>Screening; Baseline; up to Day 62</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant electrocardiogram (ECG) finding</measure>
    <time_frame>Screening; Baseline; up to Day 62</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical assessment of suicidality per the suicidality rating scale</measure>
    <time_frame>Baseline (Day -1), 24 hours after dosing (Day 2), Day 15, Day 20, Day 35 (Termination/Visit 5), up to Day 62 (unscheduled Follow-up visits)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean quality of sleep score per the Waketime Questionnaire, if necessary</measure>
    <time_frame>up to Day 62</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean maximum observed concentration (Cmax) of E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: predose; 1, 2, 3, 4, 6, and 10 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean minimum observed concentration (Cmin) of E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: predose; 1, 2, 3, 4, 6, and 10 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time from dosing to reach Cmax (tmax) of E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: predose; 1, 2, 3, 4, 6, and 10 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean area under the concentration-time curve (AUC) from time 0 to 24 hours for E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: 1, 2, 3, 4, 6, 10, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean terminal elimination half-life (t1/2) following the last day of dosing (Day 14) of E2609 and metabolites</measure>
    <time_frame>Day 14: 1, 2, 3, 4, 6, 10, 24, 48, 72, 96, and 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean average concentration calculated as AUCss/tau (Css,av), where tau is the dosing interval, of E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: 1, 2, 3, 4, 6, 10, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean accumulation ratio for AUC, Cmax, and Cmin (Rac) for E2609 and metabolites on Day 1 and Day 14</measure>
    <time_frame>Days 1 and 14: 1, 2, 3, 4, 6, 10, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance at steady state (CLss/F) of E2609 on Day 14</measure>
    <time_frame>Day 14: 1, 2, 3, 4, 6, 10, 24, 48, 72, 96, and 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with polymorphisms of N-acetyltransferase 2 (NAT2)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>E2609 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo orally once a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2609</intervention_name>
    <description>tablet</description>
    <arm_group_label>E2609 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females

          -  Aged 50 to 85 years, inclusive at time of consent

          -  Body mass index (BMI) of 17.6 to 32 kilograms per meters squared (kg/m^2) at
             Screening

        Exclusion Criteria:

          -  Personal or family history of seizure disorder, symptomatic seizures (not including a
             history of simple febrile seizures in childhood) or any past or present medical
             condition which, in the opinion of the investigator has the potential to reduce
             seizure threshold (eg, history of head trauma or concussion, previous alcohol abuse,
             substance abuse)

          -  A history of cerebrovascular accident or non-vasovagal-related loss of consciousness

          -  Any clinically significant findings on neurological examination

          -  A family history of Long QT Syndrome or a presence of other risk factors for Torsades
             de Pointes (TDP), such as hypokalemia, hypomagnesemia, or hypocalcemia

          -  History of cardiac arrhythmias, ischemic heart disease, or cerebrovascular disease

          -  A history of gastrointestinal surgery that may affect the pharmacokinetic profile of
             E2609 (eg, hepatectomy, nephrotomy, digestive organ resection)

          -  A known history of clinically significant drug or food allergies or presently
             experiencing significant seasonal allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Customer Joy Department. EJ</last_name>
    <phone>81-120-161-454</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 24, 2017</lastchanged_date>
  <firstreceived_date>February 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <keyword>E2609</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Japan</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
